A phase I, open–label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3b follicular lymphoma, or transformed lymphoma (AFT-08)
- Citation:
- Blood vol 130 (Suppl 1) 192
- Meeting Instance:
- ASH 2017
- Year:
- 2017
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- AFT
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3481
- Pharmas:
- Celgene
- Grants:
- Corr. Author:
- Authors:
- Peter Martin Nancy L. Bartlett Ildefonso Ismael Rodriguez-Rivera Maria Revuelta Julio C. Chavez John Reagan Sonali M. Smith Ann LaCasce Lei Zhang Merry Zhai Chengqing Wu John Leonard Leandro Cerchietti
- Networks:
- FL028, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, NEWMEXICO, NY018, RI005
- Study
- AFT-08
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- CC-486, DLBCL, phase I, R-CHOP